Nevertheless, later studies were able to show that expression levels of the HCCR mRNA are associated with clinical prognosis in patients with acute leukemia (AL) and they have explored the potential use as a biomarker for monitoring minimal residual disease (MRD) in AL [7]. This evidence concerns the gene LETMD1 and axial length measurement.